Catalent (NYSE:CTLT – Get Rating) issued its quarterly earnings results on Tuesday. The company reported $1.04 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.94 by $0.10, MarketWatch Earnings reports. Catalent had a net margin of 12.94% and a return on equity of 14.93%. The business had revenue of $1.27 billion for the quarter, compared to analyst estimates of $1.22 billion. During the same quarter in the prior year, the business posted $0.78 EPS. Catalent’s revenue for the quarter was up 20.9% compared to the same quarter last year.
Catalent stock traded up $11.53 during midday trading on Tuesday, hitting $101.65. 48,784 shares of the stock were exchanged, compared to its average volume of 1,325,119. Catalent has a fifty-two week low of $86.34 and a fifty-two week high of $142.64. The stock has a market capitalization of $18.21 billion, a price-to-earnings ratio of 31.12, a PEG ratio of 1.54 and a beta of 1.44. The stock’s 50-day simple moving average is $101.35 and its 200 day simple moving average is $112.85. The company has a current ratio of 2.85, a quick ratio of 2.19 and a debt-to-equity ratio of 0.94.
A number of research firms have recently weighed in on CTLT. Deutsche Bank Aktiengesellschaft cut their price objective on shares of Catalent from $129.00 to $110.00 and set a “hold” rating on the stock in a research note on Tuesday, April 12th. StockNews.com initiated coverage on shares of Catalent in a research note on Thursday, March 31st. They issued a “hold” rating on the stock. Barclays dropped their price target on shares of Catalent from $160.00 to $130.00 and set an “overweight” rating on the stock in a research report on Thursday, January 27th. Morgan Stanley decreased their price objective on shares of Catalent from $160.00 to $145.00 and set an “overweight” rating on the stock in a report on Wednesday, February 2nd. Finally, Zacks Investment Research raised shares of Catalent from a “hold” rating to a “strong-buy” rating and set a $143.00 price target on the stock in a research note on Tuesday, January 4th. Two research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Catalent currently has an average rating of “Buy” and a consensus target price of $142.88.
Several institutional investors and hedge funds have recently made changes to their positions in the business. Allianz Asset Management GmbH increased its position in shares of Catalent by 26.3% during the fourth quarter. Allianz Asset Management GmbH now owns 1,701,760 shares of the company’s stock valued at $217,886,000 after acquiring an additional 354,170 shares during the last quarter. Parametric Portfolio Associates LLC increased its position in shares of Catalent by 13.0% during the fourth quarter. Parametric Portfolio Associates LLC now owns 696,239 shares of the company’s stock valued at $89,139,000 after acquiring an additional 79,868 shares during the last quarter. Deutsche Bank AG increased its position in shares of Catalent by 1.7% during the fourth quarter. Deutsche Bank AG now owns 381,965 shares of the company’s stock valued at $48,902,000 after acquiring an additional 6,355 shares during the last quarter. Morgan Stanley increased its position in shares of Catalent by 114.0% during the second quarter. Morgan Stanley now owns 318,438 shares of the company’s stock valued at $34,430,000 after acquiring an additional 169,608 shares during the last quarter. Finally, California State Teachers Retirement System grew its holdings in shares of Catalent by 3.9% in the fourth quarter. California State Teachers Retirement System now owns 299,731 shares of the company’s stock valued at $38,375,000 after purchasing an additional 11,326 shares in the last quarter. Institutional investors and hedge funds own 98.05% of the company’s stock.
Catalent Company Profile (Get Rating)
Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates through four segments: Biologics, Softgel and Oral Technologies, Oral and Specialty Delivery, and Clinical Supply Services.
- Get a free copy of the StockNews.com research report on Catalent (CTLT)
- Another Buy The Dip Opportunity In Freshpet
- Inflation Wreaks Havoc On Haverty Furniture Company
- Tractor Supply Stock Should Plow Ahead
- MarketBeat Podcast: Investing In Innovation, Robotics, AI and Healthcare
- It’s Time to Book an Appointment for Teladoc Stock
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.